Blog
Cambium Bio Limited Annual Report FY2024
Aug 30, 2024
CEO Revised Engagement Agreement Terms
Aug 30, 2024
Appendix 4G and Corporate Governance Statement
Aug 30, 2024
Cambium 4E and Annual Report
Aug 30, 2024
Quarterly Cashflow Report & Business Update - June 2024
Jul 31, 2024
Notice of change of interests of substantial holder-Treasure
Jul 31, 2024
Notice of change of interests of substantial holder-Apex
Jul 31, 2024
Notice of change of interests of substantial holder-CMB
Jul 19, 2024
Change of directors interest
Jul 12, 2024
Share Consolidation Completion
Jul 12, 2024
Appendix 3H - Notification of cessation of securities
Jul 9, 2024
Change in substantial holding-Cyntec
Jul 4, 2024
Change in substantial holding-Treasure
Jul 2, 2024
Change in substantial holding-Apex
Jul 2, 2024
Becoming a substantial holder-Treasure
Jul 2, 2024
Becoming a substantial holder-Apex
Jul 2, 2024
Appendix 3Y-Sebastian Tseng
Jul 1, 2024
Placement Shares Cleansing Notice-Tranche 2
Jun 28, 2024
Application for quotation of securities - CMB
Jun 28, 2024
Results of General Meeting
Jun 25, 2024
Correction to Notice of General Meeting
Jun 13, 2024
Appendix 3A.3 - Security Consolidation
May 23, 2024
Notice of Share Consolidation
May 23, 2024
Letter to Shareholder - General Meeting
May 23, 2024
Notice of Meeting & proxy
May 23, 2024
Notice of General Meeting 25 June 2024 and Explanatory Statement
May 23, 2025
Becoming a substantial holder - Cyntec
May 14, 2024
Becoming a substantial holder - ZYBT
May 14, 2024
Response to ASX Aware Query
May 1, 2024
Quarterly Cashflow Report and Business Update - period ending 31 March 2024
Apr 30, 2024
Regeneus trebles on back of merger deal (Sydney Morning Herald)
Apr 5, 2024
Notice of change of interests of substantial holder
Apr 11, 2024
Director's Appointment - Dr. Tseng
Apr 11, 2024
Initial DIrector's Interest Notice - Dr. Tseng
Apr 11, 2024
Placement Shares Cleansing Notice
Apr 10, 2024
Application for quotation of securities (10 April 2024)
Apr 10, 2024
Proposed issue of securities
Apr 8, 2024
Change of company name and ASX code
Apr 8, 2024
Ceasing to be a substantial holder - Vesey
Apr 8, 2024
Ceasing to be a substantial holder - Lee
Apr 8, 2024
Ceasing to be a substantial holder - Kirman 2
Apr 8, 2024
Resignation of Non-Executive Director - Lee
Apr 5, 2024
Consideration Shares Cleansing Notice
Apr 5, 2024
Notice of initial substantial holder
Apr 5, 2024
Application for quotation of securities
Apr 5, 2024
Final Director's Interest Notice - Lee
Apr 5, 2024
Initial Director's Interest Notice - Walts
Apr 5, 2024
Initial Director's Interest Notice - Waller
Apr 5, 2024
Meet Cambium Bio team at BIO International Convention in San Diego
Apr 17, 2024
Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease
Feb 6, 2024
Process for Evaluating Board and Executive Performance
Apr 8, 2023
Whistleblower Policy
Apr 8, 2023
Securities Trading Policy
Apr 8, 2023
Shareholder Communication Policy
Apr 8, 2023
Continuous Disclosure Policy
Apr 8, 2023
Audit and Risk Committee Charter
Apr 8, 2023
Anti-Bribery and Corruption Policy
Apr 8, 2023
Code of Conduct
Apr 8, 2023
Statement of Values
Apr 8, 2023
Board Skills Matrix
Apr 8, 2023
Remuneration and Nominations Committee Charter
Apr 8, 2023
Diversity Policy
Apr 8, 2023
Board Charter
Apr 8, 2023
Corporate Governance Statement
Aug 30, 2024
Cambium Bio Limited Half Year Report (December 2023)
Dec 31, 2023
Cambium Bio Limited Annual Report FY2023
Jun 30, 2023
Cambium Bio Raises A$3.48 Million in Strategic Placement
Apr 8, 2023
Regeneus Completes Merger with Cambium Medical Technologies LLC
Apr 8, 2023
Corporate Presentation
Aug 18, 2024